United Therapeutics’ Tyvaso meets primary endpoint in IPF trial

Markets Investing.com By Investing.com 18 May 2026 20:25 1 min read

United Therapeutics’ Tyvaso meets primary endpoint in IPF trial

United Therapeutics’ Tyvaso meets primary endpoint in IPF trial

United Therapeutics’ Tyvaso meets primary endpoint in IPF trial

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.